Nektar Therapeutics (NKTR): Total Liabilities
$190.57M
As of 2025-12-31
$192.01M
As of 2026-06-30
-17.9%
3-year compound annual growth
-16.2%
5-year compound annual growth
-9.1%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $190.57M | -21.6% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $243.11M | -9.0% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $267.05M | -22.4% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $343.96M | -21.4% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $437.68M | -5.2% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $461.47M | -19.3% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $571.97M | +32.2% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $432.60M | +2.7% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $421.04M | -12.4% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $480.75M | -2.3% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $492.21M | +21.4% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $405.29M | -22.7% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $524.43M | +16.3% | 2015-02-26, Balance as of period end |
| 2012-12-31 | $450.77M | +10.3% | 2014-02-27, Balance as of period end |
| 2011-12-31 | $408.74M | -5.1% | 2013-03-01, Balance as of period end |
| 2010-12-31 | $430.56M | n/a | 2012-02-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $4.58M | -34.2% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $104.11M | -14.8% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.76M | -77.2% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $153.75M | +7.8% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
Compare NKTR, INBP, AGIO, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗